BE903497A - Composition pharmaceutique - Google Patents

Composition pharmaceutique

Info

Publication number
BE903497A
BE903497A BE0/215762A BE215762A BE903497A BE 903497 A BE903497 A BE 903497A BE 0/215762 A BE0/215762 A BE 0/215762A BE 215762 A BE215762 A BE 215762A BE 903497 A BE903497 A BE 903497A
Authority
BE
Belgium
Prior art keywords
pharmaceutical composition
reduce
cadmium
isomer
inhibit
Prior art date
Application number
BE0/215762A
Other languages
English (en)
Inventor
M Siren
Original Assignee
Siren Matti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Siren Matti filed Critical Siren Matti
Publication of BE903497A publication Critical patent/BE903497A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • A—HUMAN NECESSITIES
    • A21—BAKING; EDIBLE DOUGHS
    • A21D—TREATMENT OF FLOUR OR DOUGH FOR BAKING, e.g. BY ADDITION OF MATERIALS; BAKING; BAKERY PRODUCTS
    • A21D2/00—Treatment of flour or dough by adding materials thereto before or during baking
    • A21D2/08—Treatment of flour or dough by adding materials thereto before or during baking by adding organic substances
    • A21D2/30—Organic phosphorus compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00—Preservation of foods or foodstuffs, in general
    • A23B2/70—Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725—Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/729—Organic compounds; Microorganisms; Enzymes
    • A23B2/775—Organic compounds containing phosphorus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23B—PRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B7/00—Preservation of fruit or vegetables; Chemical ripening of fruit or vegetables
    • A23B7/14—Preserving or ripening with chemicals not covered by group A23B7/08 or A23B7/10
    • A23B7/153—Preserving or ripening with chemicals not covered by group A23B7/08 or A23B7/10 in the form of liquids or solids
    • A23B7/154—Organic compounds; Microorganisms; Enzymes
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/05—Organic compounds containing phosphorus as heteroatom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P9/00—Preparation of organic compounds containing a metal or atom other than H, N, C, O, S or halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nutrition Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)

Abstract

Composition pharmaceutique contenant en tant qu'ingrédient pharmaceutiquement actif au moins un isomère de l'inositol-triphosphate (IP3), dans une quantité suffisante pour réduire les effets négatifs du cadmium ou de l'aluminium dans le corps ou pour inhiber ou réduire la formation de radicaux libres dans le corps.
BE0/215762A 1984-10-23 1985-10-22 Composition pharmaceutique BE903497A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8405295A SE465951B (sv) 1984-10-23 1984-10-23 Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav

Publications (1)

Publication Number Publication Date
BE903497A true BE903497A (fr) 1986-02-17

Family

ID=20357457

Family Applications (2)

Application Number Title Priority Date Filing Date
BE0/215762A BE903497A (fr) 1984-10-23 1985-10-22 Composition pharmaceutique
BE0/215763A BE903498A (fr) 1984-10-23 1985-10-22 Inositol-triphosphate

Family Applications After (1)

Application Number Title Priority Date Filing Date
BE0/215763A BE903498A (fr) 1984-10-23 1985-10-22 Inositol-triphosphate

Country Status (19)

Country Link
US (7) US4777134A (fr)
EP (3) EP0179441B1 (fr)
JP (4) JPS61171789A (fr)
AT (3) ATE41853T1 (fr)
AU (3) AU589378B2 (fr)
BE (2) BE903497A (fr)
CH (2) CH666812A5 (fr)
DE (6) DE3537569A1 (fr)
DK (2) DK172857B1 (fr)
FI (3) FI82474C (fr)
FR (2) FR2571967B1 (fr)
GB (3) GB2169602B (fr)
HU (1) HU196077B (fr)
IL (1) IL76777A (fr)
IT (2) IT1190402B (fr)
NO (3) NO169010C (fr)
NZ (1) NZ213855A (fr)
SE (6) SE465951B (fr)
ZA (4) ZA858107B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0252227B1 (fr) * 1986-04-16 1994-04-13 Perstorp Ab Utilisation de l'inositol-triphosphate pour le traitement de l'intoxication par des métaux

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095035A (en) * 1981-07-31 1992-03-10 Eby Iii George A Flavor stable zinc acetate compositions for oral absorption
US5330979A (en) * 1984-10-23 1994-07-19 Perstorp Ab Method of treating renal disorders with inositoltriphosphate
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US5128332A (en) * 1984-10-23 1992-07-07 Perstorp Ab Method of treating cardiovascular diseases using inositoltrisphosphate
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
US5407924A (en) * 1984-10-23 1995-04-18 Perstorp Ab Method of treating pain using inositol triphosphate
JPS63198642A (ja) * 1986-03-11 1988-08-17 Mitsui Toatsu Chem Inc ミオイノシトール誘導体の製造方法
DE3783694T2 (de) * 1986-03-11 1993-05-19 Mitsui Toatsu Chemicals Verfahren zur herstellung von myoinositolabkoemmlingen.
US5057507A (en) * 1986-04-16 1991-10-15 Perstorp Ab Method of alleviating bone damage with inositoltriphosphate
EP0438386A4 (en) * 1986-11-05 1991-09-11 George Weston Foods Limited Novel improvers for flour and yeast raised baked goods
SE8605063D0 (sv) * 1986-11-26 1986-11-26 Matti Siren Derivatives of cyclohexane
US5274161A (en) * 1986-11-26 1993-12-28 Perstorp Ab Derivatives of cyclohexane
GB8705811D0 (en) * 1987-03-11 1987-04-15 Research Corp Ltd Inositol derivatives
JP2597618B2 (ja) * 1987-12-28 1997-04-09 三井東圧化学 株式会社 光学分割方法
JPH01287035A (ja) * 1988-05-13 1989-11-17 Sanwa Kagaku Kenkyusho Co Ltd 薬物並びにアルコール性中毒の予防剤とその治療剤
JPH01294631A (ja) * 1988-05-19 1989-11-28 Sanwa Kagaku Kenkyusho Co Ltd 糖尿性疾患治療予防剤及び飲食、し好物
SE464059C (sv) * 1988-09-15 1997-06-02 Perstorp Ab Användning av inositoltrifosfat för framställning av läkemedel
US5316770A (en) * 1989-02-16 1994-05-31 University Of Georgia Research Foundation, Inc. Vitamin D derivative feed compositions and methods of use
US5366736A (en) * 1989-02-16 1994-11-22 University Of Georgia Research Foundation, Inc. Vitamin D derivative feed compositions and methods of use
US5427956A (en) * 1989-03-08 1995-06-27 The University Of Virginia Patent Foundation Quantitative analysis for diabetic condition predictor
US5750348A (en) * 1989-03-08 1998-05-12 The University Of Virginia Patents Foundation Method for detecting insulin resistance
JPH04504847A (ja) * 1989-03-08 1992-08-27 ザ　ユニバーシティ　オヴ　バージニア　パテント　ファウンデーション インスリン抵抗性糖尿病のための食事用補添物
US5428066A (en) * 1989-03-08 1995-06-27 Larner; Joseph Method of reducing elevated blood sugar in humans
SE8902766D0 (sv) * 1989-08-17 1989-08-17 Siren Matti Saett att oeka den farmaceutiska effekten av inositolfosfat samt en beredning med foerbaettrad farmaceutisk effekt
SE8904355D0 (sv) * 1989-12-21 1989-12-21 Perstorp Ab Medicament
US7033627B2 (en) 1990-03-23 2006-04-25 Syngenta Mogen B.V. Production of enzymes in seeds and their use
KR100225087B1 (ko) * 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
US5593963A (en) * 1990-09-21 1997-01-14 Mogen International Expression of phytase in plants
US5543576A (en) * 1990-03-23 1996-08-06 Mogen International Production of enzymes in seeds and their use
SE9002278L (sv) * 1990-06-28 1991-12-29 Perstorp Ab Anvaendning av inositoltrisfosfat foer framstaellning av ett laekemedel
US6007809A (en) * 1990-08-29 1999-12-28 Chaykin; Sterling Method and product for eliminating undesirable side effects of eating vegetables such as onion or garlic
EP0546075A4 (en) * 1990-08-29 1993-07-28 Sterling Chaykin Method and product for eliminating undesirable side effects of eating vegetables such as onion or garlic
US5514398A (en) * 1990-11-05 1996-05-07 Amano Pharmaceutical Co., Ltd. Food additive and use thereof
SE9102068L (sv) * 1991-07-03 1993-01-04 Perstorp Ab Derivat av inositol, kompositioner innehaallande dessa samt anvaendning daerav
SE469260B (sv) * 1992-02-25 1993-06-14 Perstorp Ab En farmaceutisk komposition med foerbaettrad biotillgaenglighet avseende inositolfosfat
US5292537A (en) * 1992-11-12 1994-03-08 Bran Tec, Inc. Method for stabilizing rice bran and rice bran products
JP2696057B2 (ja) * 1993-05-11 1998-01-14 ニチモウ株式会社 穀類を原料とした生成物の製造方法
WO1995005830A1 (fr) * 1993-08-20 1995-03-02 The Regents Of The University Of California Agents anti-inflammatoires polyanioniques
SE502989C2 (sv) * 1993-11-22 1996-03-04 Perstorp Ab Användning av en inositoltrisfosfatester för beredning av läkemedel
SE503122C2 (sv) * 1993-11-22 1996-03-25 Perstorp Ab Användning av en inositoltrisfosfatester för behandling av inflammatoriska tillstånd
US5466465A (en) * 1993-12-30 1995-11-14 Harrogate Holdings, Limited Transdermal drug delivery system
SE502574C2 (sv) * 1994-01-25 1995-11-13 Perstorp Ab En farmaceutisk komposition med förbättrad biotillgänglighet hos inositolfosfat
US6451572B1 (en) * 1998-06-25 2002-09-17 Cornell Research Foundation, Inc. Overexpression of phytase genes in yeast systems
MXPA01009809A (es) 1999-03-31 2002-07-30 Cornell Res Foundation Inc Fosfatasas con actividad de fitasa mejorada.
US6841370B1 (en) 1999-11-18 2005-01-11 Cornell Research Foundation, Inc. Site-directed mutagenesis of Escherichia coli phytase
US6383817B2 (en) 1999-12-30 2002-05-07 Wake Forest University Cadmium is a risk factor for human pancreatic cancer
US20020193379A1 (en) * 2001-06-05 2002-12-19 Insmed Incorporated Compositions and methods for decreasing the risk of or preventing neural tube disorders in mammals
FR2828206B1 (fr) * 2001-08-03 2004-09-24 Centre Nat Rech Scient Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire
WO2003037102A2 (fr) * 2001-10-31 2003-05-08 Phytex, Llc Aliment pour animaux contenant phytase et procede correspondant
US20050108780A1 (en) * 2002-01-24 2005-05-19 Erasmus University Intracellular antibodies for a retrovirus protein
WO2003092700A1 (fr) 2002-04-29 2003-11-13 Gmp Oxycell, Inc. Inositol pyrophosphates et procede d'utilisation desdits composes
CA2925807C (fr) * 2002-09-13 2020-09-15 Cornell Research Foundation, Inc. Utilisation de mutations pour ameliorer les aspergillus phytases
CA2413240A1 (fr) * 2002-11-29 2004-05-29 Mcn Bioproducts Inc. Purification de l'inositol extrait de matieres vegetales
US20050123644A1 (en) * 2003-01-24 2005-06-09 Cargill, Incorporated Phosphate-containing fertilizer derived from steepwater
US7521481B2 (en) * 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US20050048165A1 (en) * 2003-03-31 2005-03-03 Sadanandan Bindu Process for the preparation of Chapathi dough with reduced phytic acid level
US7745423B2 (en) * 2004-07-06 2010-06-29 NormOxys, Inc Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin
US20060106000A1 (en) * 2004-07-06 2006-05-18 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20060258626A1 (en) * 2004-07-06 2006-11-16 Claude Nicolau Use of inositol-tripyrophosphate in treating tumors and diseases
US20070135389A1 (en) * 2004-07-06 2007-06-14 Claude Nicolau Tumor eradication by inositol-tripyrophosphate
WO2006102060A1 (fr) * 2005-03-18 2006-09-28 Oxyplus, Inc. Sel de calcium de myo-inositol 1,6:2,3:4,5 tripyrophosphate utile comme effecteur allosterique de l'hemoglobine
US7919297B2 (en) 2006-02-21 2011-04-05 Cornell Research Foundation, Inc. Mutants of Aspergillus niger PhyA phytase and Aspergillus fumigatus phytase
US20070212449A1 (en) * 2006-03-02 2007-09-13 Shamsuddin Abulkalam M Reduction of the titratable acidity and the prevention of tooth and other bone degeneration
US8540984B2 (en) * 2006-08-03 2013-09-24 Cornell Research Foundation, Inc. Phytases with improved thermal stability
US20080103116A1 (en) * 2006-11-01 2008-05-01 Jennings-Spring Barbara L Method of treatment and compositions of D-chiro inositol and phosphates thereof
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
US20090214474A1 (en) * 2006-11-01 2009-08-27 Barbara Brooke Jennings Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2688233A1 (fr) * 2007-05-01 2008-11-06 Normoxys, Inc. Complementation ou remplacement d'erythropoietine
US8192734B2 (en) 2007-07-09 2012-06-05 Cornell University Compositions and methods for bone strengthening
CN101951921A (zh) * 2007-09-17 2011-01-19 比奥尼里斯有限责任公司 用于治疗恶病质的方法和手段
JP5905258B2 (ja) * 2011-07-01 2016-04-20 株式会社 資生堂 血小板由来成長因子−ｂｂ産生亢進剤、並びにそれを含む間葉系幹細胞産生促進剤、幹細胞安定化剤、及び真皮再生化剤
FR3017134B1 (fr) * 2014-02-06 2018-04-20 Lesaffre Et Compagnie Levure biologique, procede d'obtention et utilisations

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2723938A (en) * 1952-12-05 1955-11-15 Bristol Lab Inc Aqueous penicillin suspensions comprising inositol phosphoric acids and their salts
US3591665A (en) * 1967-09-08 1971-07-06 Mitsui Toatsu Chemicals Process for producing phytic acid
FI51469C (fi) * 1968-01-10 1977-01-10 Morinaga Milk Industry Co Ltd Menetelmä radioaktiivisen strontium 90 saasteen poistamiseksi nestemäi sistä elintarvikkeista tai vedestä.
JPS50111246A (fr) * 1974-02-14 1975-09-01
US4154824A (en) * 1976-07-20 1979-05-15 Interx Research Corporation Nonbitter tasting potassium product for oral administration to warm-blooded animals and method for preparing same
JPS53124636A (en) * 1977-04-04 1978-10-31 Kisaku Mori Method of increasing meranine contained in animal and plant
DE2740053A1 (de) * 1977-09-06 1979-05-03 Klaus Prof Dr Med Gersonde Verwendung von allosterischen effektoren mit hilfe von lipidvesikeln ueber eine irreversible inkorporierung zwecks verbesserter o tief 2 -entladung des haemoglobins in erythrozyten
JPS5486666A (en) * 1977-12-22 1979-07-10 Ajinomoto Kk Cola beverage
JPS5798292A (en) * 1980-12-09 1982-06-18 Jiyaade:Kk Powdery phytic acid and its preparation
JPS58198254A (ja) * 1982-05-14 1983-11-18 Kyowa Hakko Kogyo Co Ltd 加工食品の品質改良法
SE450325B (sv) * 1983-02-23 1987-06-22 Tricum Ab Kostfiberprodukt baserad pa skaldelar fran froet hos ceralier
SE465951B (sv) * 1984-10-23 1991-11-25 Perstorp Ab Isomer av inositoltrifosfat foeretraedesvis i saltform foer anvaendning som terapeutiskt eller profylaktiskt medel samt kompositioner daerav
US4735902A (en) * 1984-10-23 1988-04-05 Matti Siren Stabilized composition containing inositoltriphosphate
AU2001248278A1 (en) 2000-04-13 2001-10-30 Novozymes A/S Extracellular expression of pectate lyase using bacillus or escherichia coli

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0252227B1 (fr) * 1986-04-16 1994-04-13 Perstorp Ab Utilisation de l'inositol-triphosphate pour le traitement de l'intoxication par des métaux

Also Published As

Publication number Publication date
HUT40674A (en) 1987-01-28
IT1190402B (it) 1988-02-16
JPH0515719B2 (fr) 1993-03-02
EP0179441B1 (fr) 1989-04-05
ATE37788T1 (de) 1988-10-15
US5003098A (en) 1991-03-26
EP0179439A1 (fr) 1986-04-30
ATE41853T1 (de) 1989-04-15
IL76777A0 (en) 1986-02-28
ZA858107B (en) 1986-06-25
SE8405295D0 (sv) 1984-10-23
DE3565464D1 (en) 1988-11-17
US4735936A (en) 1988-04-05
CH666812A5 (fr) 1988-08-31
GB8526079D0 (en) 1985-11-27
NO854212L (no) 1986-04-24
JPH0354924B2 (fr) 1991-08-21
NO854211L (no) 1986-04-24
FI85490B (fi) 1992-01-15
SE8503165L (sv) 1986-04-24
FI854127A0 (fi) 1985-10-22
EP0179440B1 (fr) 1990-05-23
DE3577851D1 (de) 1990-06-28
GB2167283B (en) 1989-05-24
FI82474C (fi) 1991-03-11
DK483385D0 (da) 1985-10-22
GB8526078D0 (en) 1985-11-27
DE3569188D1 (en) 1989-05-11
FI85490C (fi) 1992-04-27
IT8522574A0 (it) 1985-10-22
DE3537550A1 (de) 1986-05-15
DK483285D0 (da) 1985-10-22
NZ213855A (en) 1989-05-29
FI854127L (fi) 1986-04-24
GB2169602A (en) 1986-07-16
ZA858108B (en) 1986-06-25
FR2573080A1 (fr) 1986-05-16
SE8504968D0 (sv) 1985-10-22
EP0179439B1 (fr) 1988-10-12
HU196077B (en) 1988-09-28
US4734283A (en) 1988-03-29
GB2167298B (en) 1988-11-02
SE8504969L (sv) 1986-04-24
AU589378B2 (en) 1989-10-12
NO168227C (no) 1992-01-29
EP0179441A2 (fr) 1986-04-30
FI854128A0 (fi) 1985-10-22
FR2573080B1 (fr) 1988-11-10
FI88855C (fi) 1993-07-26
GB8526080D0 (en) 1985-11-27
AU4893185A (en) 1986-05-01
FI82474B (fi) 1990-11-30
FI854126A0 (fi) 1985-10-22
BE903498A (fr) 1986-02-17
SE465951B (sv) 1991-11-25
SE8504967L (sv) 1986-04-24
ZA858105B (en) 1986-06-25
EP0179441A3 (en) 1988-03-16
JPS61171422A (ja) 1986-08-02
JPS61171491A (ja) 1986-08-02
SE8504969D0 (sv) 1985-10-22
SE8503164D0 (sv) 1985-06-26
US4794014A (en) 1988-12-27
JPS61171789A (ja) 1986-08-02
SE8504967D0 (sv) 1985-10-22
AU582594B2 (en) 1989-04-06
FI854126L (fi) 1986-04-24
DK172857B1 (da) 1999-08-16
GB2167298A (en) 1986-05-29
NO169010B (no) 1992-01-20
NO169010C (no) 1992-04-29
ZA858106B (en) 1986-06-25
DK172852B1 (da) 1999-08-16
SE8504968L (sv) 1986-04-24
US4797390A (en) 1989-01-10
JPS61181347A (ja) 1986-08-14
FR2571967A1 (fr) 1986-04-25
FI88855B (fi) 1993-04-15
JPH0338824B2 (fr) 1991-06-11
DK483385A (da) 1986-04-24
SE8503164L (sv) 1986-04-24
EP0179440A1 (fr) 1986-04-30
SE465164B (sv) 1991-08-05
FI854128L (fi) 1986-04-24
AU4893285A (en) 1986-05-01
GB2167283A (en) 1986-05-29
SE8405295L (sv) 1986-04-24
CH668597A5 (fr) 1989-01-13
ATE53038T1 (de) 1990-06-15
AU596080B2 (en) 1990-04-26
US4777134A (en) 1988-10-11
FR2571967B1 (fr) 1988-02-05
DE3537542A1 (de) 1986-05-15
AU4893085A (en) 1986-05-01
DK483285A (da) 1986-04-24
IL76777A (en) 1990-09-17
GB2169602B (en) 1988-10-19
NO168227B (no) 1991-10-21
US4851560A (en) 1989-07-25
NO854213L (no) 1986-04-24
IT1190403B (it) 1988-02-16
DE3537569A1 (de) 1986-05-22
IT8522573A0 (it) 1985-10-22
JPH037233B2 (fr) 1991-02-01
SE8503165D0 (sv) 1985-06-26

Similar Documents

Publication Publication Date Title
AU589378B2 (en) Pharmaceutical compositions containing inositol triphosphates
ATE153855T1 (de) Zusammensetzungen zur behandlung von glaukoma die prostaglandine und clonidinderivate enthalten
ATE56356T1 (de) Brausepaare, h2-antagonisten von histamin enthaltende brausemischungen und verfahren zu ihrer herstellung.
EP0041772A3 (en) Fat emulsion containing a steroid
FR2378523A1 (fr) Medicament pour le traitement de l'acne
FR2440737A1 (fr) Emulsion de graisse pour injection intraveineuse
FR2418794A1 (fr) Analogues de la prostaglandine i2 et compositions pharmaceutiques les contenant
FR2403333A1 (fr) Analogues de la prostaglandine e1 et compositions pharmaceutiques les contenant
FR2451163A1 (fr) Emulsion insecticide huile-dans-eau et son procede de preparation
FR2430198A1 (fr) Emulsion insecticide et acaricide de type huile dans l'eau
FR2398067A1 (fr) Nouvelles 4-pyrones substituees en positions 2, 3 et 6 et medicament les contenant
GB1161349A (en) New Capillary Product
FR2399841A1 (fr) Combinaison medicamenteuse antithrombotique et procede pour sa preparation
BE904740A (fr) Utilisation (s)-(+)hydroprene pour combattre les blattes.
FR2422403A1 (fr) Compositions therapeutiques diuretiques a effet rapide, a base d'acide 4-chloro-n-furfuryl-5-sulfamoylanthranilique et de composes de pteridine
BE902055A (fr) Preparations pharmaceutiques.
BE1002624A5 (fr) Compositions pour le traitement de phlebectasies et leur procede de preparation.
BE900186A (fr) Compositions fongicides synergiques.
BE899531A (fr) Derives sulfures de l'hydantoine et compositions pharmaceutiques les contenant.
BE904146A (fr) Compositions pharmaceutiques a base de 3-aminopropoxyindoles.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: SIREN MATTI

Effective date: 19891031